SI2739153T1 - Zdravljenje raka dojke - Google Patents

Zdravljenje raka dojke

Info

Publication number
SI2739153T1
SI2739153T1 SI201231453T SI201231453T SI2739153T1 SI 2739153 T1 SI2739153 T1 SI 2739153T1 SI 201231453 T SI201231453 T SI 201231453T SI 201231453 T SI201231453 T SI 201231453T SI 2739153 T1 SI2739153 T1 SI 2739153T1
Authority
SI
Slovenia
Prior art keywords
treatment
breast cancer
breast
cancer
Prior art date
Application number
SI201231453T
Other languages
English (en)
Slovenian (sl)
Inventor
Andrew A. Protter
Jennifer Richer
Dawn Cochrane
Original Assignee
Medivation Prostate Therapeutics Llc
The Regents Of The University Of Colorado, A Body Corporate
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48192564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2739153(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc, The Regents Of The University Of Colorado, A Body Corporate filed Critical Medivation Prostate Therapeutics Llc
Publication of SI2739153T1 publication Critical patent/SI2739153T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201231453T 2011-07-29 2012-07-27 Zdravljenje raka dojke SI2739153T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161513361P 2011-07-29 2011-07-29
EP12846720.6A EP2739153B1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer
PCT/US2012/048471 WO2013066440A1 (en) 2011-07-29 2012-07-27 Treatment of breast cancer

Publications (1)

Publication Number Publication Date
SI2739153T1 true SI2739153T1 (sl) 2018-12-31

Family

ID=48192564

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201231453T SI2739153T1 (sl) 2011-07-29 2012-07-27 Zdravljenje raka dojke

Country Status (18)

Country Link
US (4) US9517229B2 (enExample)
EP (4) EP3430907A1 (enExample)
JP (2) JP6158180B2 (enExample)
KR (1) KR101923250B1 (enExample)
CN (1) CN103997894B (enExample)
BR (1) BR112014002200A2 (enExample)
CA (1) CA2843417C (enExample)
CY (1) CY1121038T1 (enExample)
DK (1) DK2739153T3 (enExample)
EA (1) EA028452B1 (enExample)
ES (1) ES2696074T3 (enExample)
HU (1) HUE040524T2 (enExample)
MX (1) MX359664B (enExample)
PH (1) PH12014500248B1 (enExample)
PL (1) PL2739153T3 (enExample)
PT (1) PT2739153T (enExample)
SI (1) SI2739153T1 (enExample)
WO (1) WO2013066440A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9517229B2 (en) * 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
GB201216017D0 (en) 2012-09-07 2012-10-24 Cancer Rec Tech Ltd Inhibitor compounds
WO2014052237A1 (en) 2012-09-26 2014-04-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EP2945628B1 (en) * 2013-01-15 2020-04-15 Aragon Pharmaceuticals, Inc. Androgen receptor modulator in combination with abiraterone acetate and prednisone for treating prostate cancer
MY189663A (en) 2013-04-17 2022-02-23 Signal Pharm Llc Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
AU2013404949B2 (en) * 2013-11-07 2018-10-18 Deciphera Pharmaceuticals, Llc Methods for inhibiting TIE2 kinase useful in the treatment of cancer
JP6945587B2 (ja) * 2013-11-07 2021-10-06 デシフェラ ファーマシューティカルズ，エルエルシー ガンの処置に有用なｔｉｅ２キナーゼの阻害方法
JP6648040B2 (ja) * 2014-05-28 2020-02-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 がん治療のための併用療法としてのエリブリン及びポリ（ａｄｐリボース）ポリメラーゼ（ｐａｒｐ）阻害剤の使用
BR112017012142A2 (pt) * 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama
CA2977397A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Dual loaded liposomal pharmaceutical formulations
WO2016141167A1 (en) 2015-03-03 2016-09-09 Cureport, Inc. Combination liposomal pharmaceutical formulations
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
US9963433B2 (en) * 2016-01-29 2018-05-08 Wayne State University Anticancer drugs including the chemical structures of an androgen receptor ligand and a histone deacetylase inhibitor
IL271491B2 (en) 2017-06-22 2023-09-01 Celgene Corp Treatment of carcinoma of the liver characterized by hepatitis b virus infection
KR20240096623A (ko) 2017-10-16 2024-06-26 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
CN107987055A (zh) * 2017-12-19 2018-05-04 刘秀云 硫代咪唑二酮类雄激素受体拮抗剂及其用途
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
KR102708177B1 (ko) 2018-01-31 2024-09-23 데시페라 파마슈티칼스, 엘엘씨. 위장관 기질 종양의 치료를 위한 병용 요법
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
AU2019387367A1 (en) * 2018-11-30 2021-06-10 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
IL330104A (en) 2019-03-11 2026-08-01 Deciphera Pharmaceuticals Llc Crystalline forms of rifatinib
US12691108B2 (en) 2019-08-12 2026-07-28 Deciphera Pharmaceuticals, Llc Methods for treating vascular malformations
HRP20260411T1 (hr) 2019-08-12 2026-05-08 Deciphera Pharmaceuticals, Llc Ripretinib za liječenje gastrointestinalnih stromalnih tumora
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
EP4188330A4 (en) * 2020-08-03 2024-09-04 Oncocyte Corporation CLASSIFICATION OF TUMORS AND PREDICTION OF RESPONSE
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
NZ564223A (en) * 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
CA2630974A1 (en) 2005-11-23 2007-05-31 University Of Utah Research Foundation Methods and compositions involving intrinsic genes
BRPI0709771B1 (pt) * 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
NZ596260A (en) 2006-03-29 2013-05-31 Univ California Diarylthiohydantoin compounds
TWI469971B (zh) 2007-10-26 2015-01-21 Univ California 二芳基乙內醯脲類化合物
US8450290B2 (en) * 2007-11-26 2013-05-28 Enzon Pharmaceuticals, Inc. Methods for treating androgen receptor dependent disorders including cancers
WO2009114534A1 (en) * 2008-03-14 2009-09-17 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
SI2297359T1 (sl) 2008-05-30 2014-05-30 The University Of North Carolina At Chapel Hill Profili genskega izraĹľanja za napovedovanje izida raka dojke
JP2012518661A (ja) 2009-02-24 2012-08-16 メディベイション プロステイト セラピューティクス， インコーポレイテッド 特定のジアリールヒダントインおよびジアリールチオヒダントイン化合物
EP2416657A4 (en) 2009-04-09 2012-09-05 Medivation Prostate Therapeutics Inc COMPOUNDS COMPRISING SUBSTITUTED DI-ARYLHYDANTOIDS AND DI-ARYLTHIOHYDANTOINES AND METHODS OF USE THEREOF
US8507195B2 (en) 2009-08-20 2013-08-13 The Regents Of The University Of Colorado MiRNAs dysregulated in triple-negative breast cancer
WO2011044327A1 (en) * 2009-10-07 2011-04-14 Medivation Prostate Therapeutics, Inc. Substituted phenylcarbamoyl alkylamino arene compounds and n,n'-bis-arylurea compounds
JP5971769B2 (ja) 2011-03-15 2016-08-17 ザ ユニバーシティー オブ ノースカロライナ アット チャペル ヒル アントラサイクリン療法を用いて乳癌を処置する方法
US9517229B2 (en) * 2011-07-29 2016-12-13 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
WO2013082440A2 (en) 2011-11-30 2013-06-06 The University Of North Carolina At Chapel Hill Methods of treating breast cancer with taxane therapy
WO2014031164A1 (en) 2012-08-23 2014-02-27 The Regents Of The University Of Colorado, A Body Corporate Method for determining breast cancer treatment
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
US10679730B2 (en) 2013-05-28 2020-06-09 The University Of Chicago Prognostic and predictive breast cancer signature
BR112017012142A2 (pt) 2014-12-12 2018-01-02 Medivation Prostate Therapeutics Inc método para predição da resposta a agentes terapêuticos para o câncer de mama e método de tratamento de câncer de mama

Also Published As

Publication number Publication date
US20210069154A1 (en) 2021-03-11
US20170087132A1 (en) 2017-03-30
EP3430907A1 (en) 2019-01-23
MX2014001218A (es) 2014-08-22
KR20140107174A (ko) 2014-09-04
ES2696074T3 (es) 2019-01-14
EP2739153B1 (en) 2018-08-22
US20190262315A1 (en) 2019-08-29
US20140296312A1 (en) 2014-10-02
KR101923250B1 (ko) 2018-11-28
CY1121038T1 (el) 2019-12-11
DK2739153T3 (en) 2018-12-03
EA201400178A1 (ru) 2014-11-28
JP2014524934A (ja) 2014-09-25
EP3610731A1 (en) 2020-02-19
WO2013066440A9 (en) 2013-07-18
CN103997894B (zh) 2016-08-24
EP2739153A4 (en) 2015-03-11
CA2843417C (en) 2018-08-21
PT2739153T (pt) 2018-11-28
EA028452B1 (ru) 2017-11-30
US9517229B2 (en) 2016-12-13
JP2017141269A (ja) 2017-08-17
MX359664B (es) 2018-10-05
US10111861B2 (en) 2018-10-30
HK1198867A1 (en) 2015-06-19
EP3791724A1 (en) 2021-03-17
HUE040524T2 (hu) 2019-03-28
WO2013066440A1 (en) 2013-05-10
HK1201413A1 (en) 2015-09-04
JP6158180B2 (ja) 2017-07-05
CN103997894A (zh) 2014-08-20
EP2739153A1 (en) 2014-06-11
CA2843417A1 (en) 2013-05-10
PH12014500248B1 (en) 2018-08-31
BR112014002200A2 (pt) 2017-03-07
PH12014500248A1 (en) 2014-03-17
PL2739153T3 (pl) 2019-04-30

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
PH12014500248A1 (en) Treatment of breast cancer
GB2495841B (en) Phytocannabinoids for use in the treatment of breast cancer
IL232530A0 (en) Combined cancer treatment
EP2751267A4 (en) METHOD FOR THE TREATMENT OF BREAST CANCER
SG11201501653RA (en) Methods for the treatment of locally advanced breast cancer
IL232890A0 (en) Immunogenic therapy for cancer
SG10201508495VA (en) Combination treatment of cancer
IL228411A0 (en) Treatment of solid tumors
IL228430A0 (en) Cancer treatment
IL226247A0 (en) Cancer treatment methods
EP2903644A4 (en) TREATMENT OF CANCER
EP2640390A4 (en) METHODS OF TREATING CANCER
GB201217892D0 (en) Treatment of cancer
GB201412831D0 (en) Detection and treatment of breast cancer
GB201217890D0 (en) Treatment of cancer
IL237229A0 (en) Methods of treating cancer using lipoplatin
GB201121783D0 (en) Treatment of cancer
GB201121791D0 (en) Combination treatment of cancer
GB201200262D0 (en) Therapy of breast cancer
GB201208296D0 (en) Treatment of cancer
GB201017354D0 (en) Treatment of cancer
IL232266A0 (en) Cancer treatment methods
GB201222949D0 (en) Combination Treatment of Cancer
GB201222950D0 (en) Combination treatment of cancer